104167-26-2

Upstream product

• 104894-25-9 C₁₅H₂₂NO₅P 
• 88-72-2 1-methyl-2-nitrobenzene 
• 3958-60-9 2-nitrophenylmethyl bromide 
• 79202-15-6 diethyl (hydroxy)(2-nitrophenyl)methylphosphonate 
• 140150-99-8 diethyl <<2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)phenyl>methyl>phosphonate 
• 4914-12-9 diethyl 2-nitrobenzylphosphonate 
• 2464-33-7 N-(2-methylphenyl)phthalimide 
• 57365-06-7 2-<2-(bromomethyl)phenyl>-1H-isoindole-1,3(2H)-dione 
• 552-89-6 2-nitro-benzaldehyde 

Downstream Products

• 1158382-83-2 diethyl 2-(n-pentylsulfonamido)benzylphosphonate 
• 1158382-86-5 diethyl 2-(n-nontylsulfonamido)benzylphosphonate 
• 54006-12-1 2-aminobenzylphosphine 

Relevant academic research and scientific papers

Poly(o-aminobenzylphosphonic acid): a Novel Water Soluble, Self-doped Functionalized Polyaniline

A novel self-doped polymer having alkylphosphonic acid moieties on polyaniline is synthesized from persulfate oxidative coupling of o-aminobenzylphosphonic acid 3; the resulting polymer, apart from being water soluble in its self-doped monosodium salt for

A new water-soluble, self-doping conducting polyaniline from poly(o-aminobenzylphosphonic acid) and its sodium salts: Synthesis and characterization

Poly(o-aminobenzylphosphonic acid) and its sodium salts, made by progressive neutralization with NaOH, have been prepared and characterized. Both the hemisodium and monosodium salts are intrinsically self-doped and water-soluble in the conducting form. Th

Discovery and characterization of aryl isonitriles as a new class of compounds versus methicillin- and vancomycin-resistant Staphylococcus aureus

Methicillin- and vancomycin-resistant Staphylococcus aureus (MRSA and VRSA) have emerged as a global health concern. A new class of compounds featuring an aryl isonitrile moiety has been discovered that exhibits potent inhibitory activity against several clinically-relevant MRSA and VRSA isolates. Structure-activity relationship studies have been conducted to identify the aryl isonitrile group as the key functional group responsible for the observed antibacterial activity. The most potent antibacterial aryl isonitrile analogs (MIC 2 μM) did not show any toxicity against mammalian cells up to a concentration of 64 μM.

A tripodal benzylene-linked trisamidophosphine ligand scaffold: Synthesis and coordination chemistry with group(IV) metals

A new tripodal trisamidophosphine ligand (1) based on the trisbenzylphosphine backbone has been synthesized in three steps starting from NaPH2 and phthaloyl-protected 2-aminobenzyl bromide. At elevated temperatures, 1 reacts directly with M(NMe

NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, METHODS OF USE FOR SAME, AND METHODS FOR PREPARING SAME

The present invention relates to a novel class of compounds comprising formula I, wherein n is 0 or 1. A is NR1, O, or S, wherein R1 is H, hydroxyl, C1-C10 alkyl, C1-C10 alkoxy, alkenyl, aryl, alkylaryl or arylalkyl. X is a carboxylate, a phosphonate, or a phosphate residue, or a C1-C10 alkyl residue optionally substituted with a carboxylate, phosphonate or phosphate residue. Y is a C1-C20 alkyl, alkenyl, halide, hydroxyl, C1-C20 alkoxy, aryl, alkylaryl, arylalkyl, cycloalkyl, cycloalkenyl, or a heterocyclic ring and is optionally substituted with one or more halides. Z is a H, a hydroxyl group, a halide, an aryl group, an alkylaryl group, an arylalkyl group, a cycloalkyl group, a cycloalkenyl group or a heterocyclic ring and is optionally substituted with one or more C1-C10 alkyl groups, C1-C10alkoxy groups, hydroxyl groups, cyano groups, carboxylate groups, halides, aryl groups, alkylaryl groups, arylalkyl groups, cycloalkyl groups, cycloalkenyl groups or heterocyclic rings.

Design and synthesis of small molecule glycerol 3-phosphate acyltransferase inhibitors

The incidence of obesity and other diseases associated with an increased triacylglycerol mass is growing rapidly, particularly in the United States. Glycerol 3-phosphate acyltransferase (GPAT) catalyzes the ratelimiting step of glycerolipid biosynthesis, the acylation of glycerol 3-phosphate with saturated long-chain acyl-CoAs. In an effort to produce small molecule inhibitors of this enzyme, a series of benzoic and phosphonic acids was designed and synthesized. In vitro testing of this series has led to the identification of several compounds, in particular 2-(nonylsulfonamido)benzoic acid (15g), possessing moderate GPAT inhibitory activity in an intact mitochondrial assay.

AMIDES AS SPHINGOMYELINE INHIBITORS

The present invention, relates to compounds of formula (I), wherein A is hydrogen or (C1-4)alkyl, R1 is a group Y-R2, Y is not present or is (C1-4)alkylene, which alkylene optionally is substituted, e.g. one or

Discovery of novel phosphonic acid derivatives as new chemical leads for inhibitors of TNF-α production

2-(Acylamino)benzylphosphonic acid 6 derived from an artificial substrate of sphingomyelinase was found to show inhibitory activity of TNF-α production. Structural optimization was started with the chemical modification of 6. The discovery of another chem

A novel protocol for construction of indolylmethyl group at aldehydes or ketones

A new method for introduction of indolylmethyl group to aldehydes or ketones using diethyl (o-isocyanophenylmethyl) phosphonate through Horner-Wadsworth-Emmons condensation, thiolmediated radical cyclization, and the subsequent desulfurization is described. The Horner-Wadsworth-Emmons reagent was prepared from 2-nitrobenzaldehyde in a concise three-step sequence.

Exploration of N-Phosphonoalkyl-, N-Phosphonoalkenyl-, and N-(Phosphonoalkyl)phenyl-Spaced α-Amino Acids as Competitive N-Methyl-D-aspartic Acid Antagonists

A series of N-substituted α-amino acids containing terminal phosphonic acid groups has been synthesized as potential N-methyl-D-aspartate (NMDA) receptor antagonists.NMDA receptor affinity was determined by displacement of a known ligand (CPP) from crude rat brain synaptic membranes; an antagonists action was demonstrated by the inhibition of glutamate-induced accumulation of (45Ca2+> in cultured rat cortical neurons.Receptor affinity was significantly correlated with antagonist activity (Figure 1).Moderate affinity (IC50 = 1-2 μM) was retained for analogues (31 and 32, Table I; and 59 and 66, Table II) with reduced flexibility in their phosphonate side chains and is consistent with entropy playing a role in determining receptor affinity.Modeling studies suggest a folded conformation that brings the distal phosphonic acid group into close proximity with the α-carboxylate is required for binding.Each of the active analogues possess entropy-limiting features (double bonds, phenyl rings) in their side chains that allows the superposition of their key NH2, α-COOH, and distal PO3H2 groups with those of known competitive antagonists.Affinity decreased for analogues with α-carbon substitution, presumably because the α-substituent inhibits the folding of these structures into a bioactive conformation and occupies receptor-excluded volume.A complete description of the NMDA antagonist pharmacophore model is provided in a companion paper.